Abstract 237P
Background
There is paucity of data of role of PARP inhibitors (PARPi) in BRCA mutation (gBRCAm) positive platinum resistant ovarian cancer (OC) disease. We report here analysis of outcome of PARPi treatment in patients including those with platinum resistant disease.
Methods
In this study, we analyzed efficacy of PARPi in all consecutive patients of OC with gBRCAm who received the drug. The drug was procured through compassionate program.
Results
Between July 1, 2015 and June 30, 2019, 28 patients received PARPi. At the time of data censoring (June 30, 2019), 6 (21.4%) patients are still on treatment. 5 patient received Talazoparib and 23 Olaparib. Median age is 54.5 years (range 39-75). BRCAm 1 positive patients were 20. Median number of previous lines of chemotherapy received were 3 (range 1-6). 7 platinum sensitive patients received the drug as maintenance (3 in complete response [CR] and 4 in partial response [PR]) while 21 had platinum resistant progressive disease. Overall response rate (ORR) was 82% with CR as the best response in 5 which also includes 3 patients who received the drug while in CR and maintained it. With the median treatment duration (mTD) of 14.14 months (95%CI 8.43-23.33), 71.4 % patients eventually progressed. The median follow up was 15.3 months (range 4- 42.6 months). The median overall survival (OS) was 32.9 months (95% CI 13.03 NR) The below table describes results of 21 platinum resistant patients. With the mTD of 10.4 months (95%CI 8.17 23.33), 86 % patients had progressed. Three (14%) platinum resistant patients are still on treatment with the treatment duration (TD) of 5.47, 32.9 and 37 months.
Table: 237P
Response | N (%) |
---|---|
ORR | 16 (76) |
CR | 1 (4.7) |
PR | 15 (71.4) |
PD | 5 (24) |
Median OS in months (95% CI) | 28.8 (9.6 NR) |
Progression free survival was not calculated as disease assessment was not done at defined time point. The TD was taken as the surrogate marker for efficacy. Grade ≥3 side effects were documented in 33% patients (anemia 23.5%, thrombocytopenia 17.6%, fatigue 25%).
Conclusions
This study suggests that PARPi is a viable treatment option in patients of platinum resistant OC with gBRCAm. This should be further evaluated in randomized clinical controlled trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Amit Agarwal.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO20 - Can "Superman" have Chronic Myelomonocytic Leukemia?
Presenter: Alexander Luchinin
Session: Poster display session
Resources:
Abstract
YO21 - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.
Presenter: Irappa Madabhavi
Session: Poster display session
Resources:
Abstract
YO22 - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma
Presenter: Mel Valerie Cruz-Ordinario
Session: Poster display session
Resources:
Abstract
YO23 - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report
Presenter: Emmelyn Buenacosa-Nepucpan
Session: Poster display session
Resources:
Abstract
YO25 - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.
Presenter: Izzati Rosli
Session: Poster display session
Resources:
Abstract
YO26 - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.
Presenter: Minako Nishio
Session: Poster display session
Resources:
Abstract
YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis
Presenter: Pradip Bhandari
Session: Poster display session
Resources:
Abstract
YO28P - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)
Presenter: Nur Faizah Ab Muin
Session: Poster display session
Resources:
Abstract
YO29 - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report
Presenter: Ritsu Ibusuki
Session: Poster display session
Resources:
Abstract
YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach
Presenter: Rich Ericson King
Session: Poster display session
Resources:
Abstract